Filters
Valacyclovir appears to have little benefit in the treatment of individuals with early symptomatic Alzheimer’s disease (AD) and herpes simplex virus (HSV) seropositivity, according to the results of the phase II VALAD study.
In the secondary analysis of the TASTE trial, tenecteplase is associated with better clinical outcomes than alteplase in individuals with distal vessel occlusions (DVOs).
Among patients with epilepsy in Singapore, those who use multiple antiseizure medications (ASMs) face a substantial burden of hospitalization, according to a study.
New research suggests that moderate intake levels of caffeinated coffee and tea may reduce the risk of dementia and produce modest improvements in cognitive function.
At the Microbiome Summit 2026, experts shared insights into how the gut microbiome can be modulated to support healthy ageing.
In patients with non–large vessel occlusion acute ischemic stroke and salvageable brain tissue, administering intravenous tenecteplase between 4.5 and 24 h after stroke onset helps increase the chances of having an excellent functional outcome, although it contributes to an increased risk of symptomatic intracranial haemorrhage, according to a study.
For patients with acute ischaemic stroke caused by a large-vessel occlusion, infusing alteplase into the artery after successful endovascular thrombectomy is beneficial, conferring functional gains and reducing persistent hypoperfusion, as shown in the phase III open-label CHOICE-2 trial.
Cenobamate demonstrates superior effectiveness over other newer-generation antiseizure medications (ASMs) in the treatment of adult patients with drug-resistant focal epilepsy, according to a pooled analysis of four real-world studies.
In patients with acute ischaemic stroke, administration of loberamisal, a novel neuroprotective agent, within 48 hours of symptom onset improves functional outcomes, according to the LAIS* trial presented at ISC 2026.
The oral factor XIa (FXIa) inhibitor asundexian scores high for secondary prevention in patients with non-cardioembolic stroke or high-risk transient ischaemic attack (TIA) who are receiving standard antiplatelet therapy, having met its primary efficacy and safety endpoints in the phase III OCEANIC-STROKE trial.
